Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors

Chemistry & Biology
Peter CanningAlex N Bullock

Abstract

RIPK2 mediates pro-inflammatory signaling from the bacterial sensors NOD1 and NOD2, and is an emerging therapeutic target in autoimmune and inflammatory diseases. We observed that cellular RIPK2 can be potently inhibited by type II inhibitors that displace the kinase activation segment, whereas ATP-competitive type I inhibition was only poorly effective. The most potent RIPK2 inhibitors were the US Food and Drug Administration-approved drugs ponatinib and regorafenib. Their mechanism of action was independent of NOD2 interaction and involved loss of downstream kinase activation as evidenced by lack of RIPK2 autophosphorylation. Notably, these molecules also blocked RIPK2 ubiquitination and, consequently, inflammatory nuclear factor κB signaling. In monocytes, the inhibitors selectively blocked NOD-dependent tumor necrosis factor production without affecting lipopolysaccharide-dependent pathways. We also determined the first crystal structure of RIPK2 bound to ponatinib, and identified an allosteric site for inhibitor development. These results highlight the potential for type II inhibitors to treat indications of RIPK2 activation as well as inflammation-associated cancers.

References

Jan 16, 2003·The Journal of Biological Chemistry·Stephen E GirardinPhilippe J Sansonetti
Jun 7, 2003·Science·Stephen E GirardinDana J Philpott
Oct 20, 2007·The Journal of Biological Chemistry·Yibin YangMichelle A Kelliher
Oct 30, 2007·The Journal of Biological Chemistry·Jae-Young KimJun Ninomiya-Tsuji
Mar 7, 2009·Inflammatory Bowel Diseases·Anna NegroniSalvatore Cucchiara
May 29, 2009·The Journal of Biological Chemistry·Chiara NembriniBenjamin J Marsland
Dec 3, 2010·Genes & Development·Justine T Tigno-AranjuezDerek W Abbott
Mar 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Klaus MrossOlaf Christensen
May 23, 2012·Molecular Cell·Rune Busk DamgaardMads Gyrd-Hansen
Jun 12, 2012·Cancer Discovery·Rita AndraosThomas Radimerski
Oct 31, 2012·Molecular and Cellular Biology·Justine T Tigno-AranjuezDerek W Abbott
Jan 3, 2013·The Journal of Clinical Investigation·Aurélie Couturier-MaillardMathias Chamaillard
Mar 12, 2013·Structure·Tian XieYigong Shi
Jun 25, 2013·Journal of Leukocyte Biology·Janice C JunDerek W Abbott
Jun 29, 2013·Molecular Cell·Berthe Katrine FiilMads Gyrd-Hansen
Jul 3, 2013·EMBO Molecular Medicine·Rune Busk DamgaardMads Gyrd-Hansen
Oct 8, 2013·Cell Reports·Tian XieYigong Shi
Oct 25, 2013·Nature Reviews. Cancer·Eran ElinavRichard A Flavell
Nov 5, 2013·The New England Journal of Medicine·J E CortesUNKNOWN PACE Investigators
Mar 13, 2014·Clinical and Experimental Immunology·S AmmannC Speckmann
Jul 30, 2014·Frontiers in Immunology·Mansi Saxena, Garabet Yeretssian
Sep 13, 2014·The Journal of Biological Chemistry·Justine T Tigno-AranjuezDerek W Abbott
Dec 20, 2014·Immunity·Roberta CarusoGabriel Núñez

❮ Previous
Next ❯

Citations

Feb 22, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Josiane V CruzCleydson B R Santos
Jul 28, 2018·Journal of Leukocyte Biology·Madelyn H MillerJustine T Tigno-Aranjuez
Aug 15, 2018·Journal of Leukocyte Biology·Barun Poudel, Prajwal Gurung
Mar 21, 2018·The Journal of Pharmacology and Experimental Therapeutics·Mohamed SallaShairaz Baksh
Jul 22, 2018·The EMBO Journal·Matous HrdinkaMads Gyrd-Hansen
May 31, 2020·Endocrinology·Brittany M DugganJonathan D Schertzer
Nov 15, 2018·Cancers·Francesca MusumeciSilvia Schenone
Feb 20, 2020·Science Signaling·Simone JensenOle Haagen Nielsen
Nov 11, 2017·Scientific Reports·Jéssica Cristina Dos SantosLeo A B Joosten
Jan 12, 2019·F1000Research·Najoua Lalaoui, David Lawrence Vaux
Aug 6, 2019·Frontiers in Immunology·Thomas P ChapmanAlison Simmons
Apr 6, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Steven M ChirieleisonDerek W Abbott
May 23, 2019·Frontiers in Immunology·Daniele CorridoniAlison Simmons
Oct 22, 2019·Frontiers in Cell and Developmental Biology·Valentin J HeimUeli Nachbur
Dec 15, 2020·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Sigrun Ruth HofmannFelix Schulze
Aug 30, 2020·Seminars in Cell & Developmental Biology·Vik Ven EngJaclyn S Pearson
Aug 1, 2020·Seminars in Cell & Developmental Biology·Gregory D Cuny, Alexei Degterev
Feb 11, 2021·ACS Infectious Diseases·Matthew A HulversonWesley C Van Voorhis
May 1, 2018·Structure·Christine S HuangSarah G Hymowitz
Jun 16, 2017·Veterinary Immunology and Immunopathology·Dan-Dan XuRui Wu
Jun 3, 2021·Cell Discovery·Huyan MengYing Li
May 16, 2017·Journal of Medicinal Chemistry·Zakey Yusuf BuuhRongsheng E Wang
Mar 19, 2020·ACS Medicinal Chemistry Letters·Amy C HartWilliam J Pitts
Oct 23, 2018·ACS Medicinal Chemistry Letters·Pamela A HaileRobert W Marquis
Jun 6, 2018·Journal of Medicinal Chemistry·Marian C Bryan, Naomi S Rajapaksa
Nov 22, 2019·ACS Medicinal Chemistry Letters·Curt D HaffnerRobert W Marquis

❮ Previous
Next ❯

Methods Mentioned

BETA
thermal shift
gel filtration
Ubiquitination
size-exclusion chromatography
thermal
PCR
flow cytometry

Software Mentioned

Treestar
GraphPad
FlowJo
Prism

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.